In recent years, healthcare databases have become increasingly important because of their potential to rapidly conduct analyses aimed at evaluating the pattern of use and the benefit-risk profile of drugs through data from clinical practice. Scientific evidence on potential benefits and risks of drugs, derived from the analysis of Real World Data and therefore relating to the use of drugs in the real-world setting, is known as Real World Evidence and it is fundamental to integrate pre-marketing evidence on drugs generated by clinical trials. If Real World Evidence is based on the analysis of good-quality data and on the correct interpretation of the results, it constitutes a valid support for regulatory decision-making. Many experiences have been conducted in order to optimize the use of Big Data and to apply artificial intelligence in several areas of medicine, including pharmacovigilance.

In Italy, data infrastructures have been created from clinical practice, by integrating claims data with data from clinical registries of local networks and data collected during active surveillances. Clinical registries have been also used in several European countries to conduct post-marketing studies on the safety of drugs used for the treatment of immune-mediated inflammatory diseases (IMID). Furthermore, in the United States, the Biologic and Biosimilar Collective Intelligence Consortium (BBCIC) was established in 2015. It is a non-profit research network with the aim of conducting observational analysis on the safety and efficacy of biological drugs.

All these infrastructures play a key role in the evaluation of the risk-benefit profiles of biological drugs. Biological drugs have revolutionized the treatment of IMID in different therapeutic areas, especially in the dermatology, rheumatology, gastroenterology and onco-hematology setting. However, the use of these drugs has been associated with the onset of several safety issues, including hypersensitivity and immunogenicity reactions, infections and malignancies. Moreover, with the current pandemic caused by SARS-CoV-2, there is uncertainty about the prognosis of COVID-19 in patients chronically treated with biological drugs. Because of these issues, it is necessary to monitor biological drugs, facing challenges related to data infrastructure, in order to obtain useful and updated large-scale clinical data relating to the safety of biological drugs.

The sixth edition of this symposium aims at comparing the needs and priorities of the institutional/regulatory world and the scientific experience of national and international research groups on the generation of Real World Evidence, in order to conduct post-marketing evaluations on the benefit-risk profile of biological drugs.
Agenda:

22nd September 2021

10:30-10:45 am - Welcome
Professor Giorgio Racagni – President of the Italian Society of Pharmacology - SIF
Professor Gianluca Trifirò – Full Professor of Pharmacology – Department of Diagnostics and Public Health, University of Verona
Dr. Mira Harrison-Woolrych – President of the International Society of Pharmacovigilance

1st session
10:45 am - 1:45 pm – Italian Experience (in Italian)

Moderators: Francesco Trotta – HTA Division at the Italian Medicines Agency (AIFA) – Invited (TBC)
Nello Martini – ReS Foundation

- 10:45 am - 11:05 am - The role of registries to conduct post-marketing surveillance: the example of monoclonal antibodies for the treatment of COVID-19
  Pierluigi Russo - Monitoring Registers Office, Italian Medicines Agency (AIFA)

- 11.05 am – 11:25 am – From the Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net) to the PsoMother Project
  Valeria Belleudi - Department of Epidemiology, Lazio Regional Health Service

- 11:25 am - 11:45 am - A multi-Regional distributed database network for post-marketing surveillance of biological drugs: the VALORE Project
  Ylenia Ingrasciotta – Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina

- 11:45 am - 12:00 pm - Discussion

- 12.00 pm - 1.30 pm - Round table “Which priorities for the post-marketing monitoring of biological drugs in clinical practice?”
  Moderators: Gianluca Trifirò - Department of Diagnostics and Public Health, University of Verona
  Antonio Addis - Department of Epidemiology, Lazio Regional Health Service; Scientific Technical Committee, Italian Medicines Agency

Carlo Salvarani – University of Modena and Reggio Emilia; Unit of Rheumatology - IRCCS “S. Maria Nuova”, Reggio Emilia
Luigi Naldi - Department of Dermatology – San Bortolo Hospital AULSS 8 Berica, Vicenza; GISED Study Center
Stefano Collatina – Egualia Industrie Farmaci Accessibili
Giovanna Scroccaro – Head of Pharmaceutical and Medical Device Department, Veneto Region
Anna Rosa Marra – Head of Post-Marketing surveillance – Italian Medicines Agency (AIFA)
Anna Maria Porrini – Roche – Medical Director – Roche
Farindustria - (TBC)

1:30 pm - 1:45 pm - Discussion

1:45 pm - 2:30 pm – Break

2nd Session

2:30 pm - 4:30 pm - Overview of research network and international real-world studies for post-marketing surveillance of biological drugs (In English)

Moderators: Jessica Jalbert - Regeneron Pharmaceuticals
Ursula Kirchmayer - Department of Epidemiology, Lazio Regional Health Service

- 2:30 pm - 2:50 pm - Post-marketing surveillance of biological drugs: US experience
  Seoyoung C. Kim - Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston

- 2:50 pm – 3:10 pm - Priorities for post-marketing surveillance of biological drugs: regulatory perspective
  Helga Gardarsdottir - Drug Regulatory Sciences at the Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

- 3:10 pm - 3:30 pm – The experience of the DANBIO Registry
  Bente Glintborg - The DANBIO registry, Rigshospitalet, and Department of Rheumatology, Gentofte and Herlev University Hospital – Invited (TBC)

- 3:30 pm - 3:50 pm - The experience of the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)
  Cate Lockhart - Executive Director, Biologics and Biosimilars Collective Intelligence Consortium- BBCIC

- 3:50 pm - 4:10 pm – TheShinISS: a tool for conducting distributed analyses in pharmacoepidemiology studies on biological drugs
  Marco Massari/Stefania Spila Alegiani - Pharmacoepidemiology Unit, National Center for Research and Pre-clinical and Clinical Evaluation of Drugs, National Heath Institute

- 4:10 pm - 4.30 pm – Discussion

Conclusions
SCIENTIFIC COMMITTEE

Trifirò Gianluca – Full Professor of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Italy

Moretti Ugo - Associate Professor of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Italy

Chiamulera Cristiano - Full Professor of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Italy

Guarnieri Claudio – Associate Professor of Dermatology, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy

Tuccori Marco - Pharmacovigilance Manager, University Hospital of Pisa, Italy

FACULTY

Addis Antonio – Researcher at the Department of Epidemiology, Lazio Regional Health Service; Member of the Scientific Technical Committee, Italian Medicines Agency (AIFA), Italy

Belleudi Valeria – Data manager at the Department of Epidemiology, Lazio Regional Health Service, Italy

Collatina Stefano – Coordinator Biosimilar Group of Egualia Industrie Farmaci Accessibili

Gardarsdottir Helga - Associate Professor of Drug Regulatory Sciences at the Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

Glintborg Bente - Clinical Associate Professor, The DANBIO registry, Rigshospitalet, and Department of Rheumatology, Gentofte and Herlev University Hospital

Ingrasciotta Ylenia – Research fellow at the Department of Biomedical and Dental Sciences and Morphofunctional Imaging University of Messina, Italy

Jalbert Jessica - Senior Director HEOR - Epidemiology at Regeneron Pharmaceuticals, US

Kim C. Seoyoung - Associate Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, US

Kirchmayer Ursula – Pharmacist at the Department of Epidemiology, Lazio Regional Health Service

Lockhart Cate - Executive Director, Biologics and Biosimilars Collective Intelligence Consortium-BBCIC, US

Marra Anna Rosa – Head of Post-Marketing surveillance – Italian Medicines Agency (AIFA), Italy

Martini Nello – President of ReS Foundation, Italy

Massari Marco – Researcher at the Pharmacoepidemiology Unit, National Center for Research and Pre-clinical and Clinical Evaluation of Drugs, National Health Institute, Italy

Naldi Luigi – Head of the Department of Dermatology – San Bortolo Hospital AULSS 8 Berica, Vicenza; GISED Study Center, Italy

Palmisano Riccardo – President of Assobiotech, Italy

Porrini Anna Maria – Medical Director – Roche, Italy

Russo Pierluigi – Head of the Monitoring Registers Office - Italian Medicines Agency (AIFA), Italy

Salvarani Carlo – Full Professor of Rheumatology, University of Modena and Reggio Emilia; Head of Unit of Rheumatology - IRCCS “S. Maria Nuova”, Reggio Emilia, Italy

Scroccaro Giovanna – Head of Pharmaceutical and Medical Device Department, Veneto Region, Italy

Spila Alegiani Stefania – Researcher at the Pharmacoepidemiology Unit, National Center for Research and Pre-clinical and Clinical Evaluation of Drugs, National Health Institute, Italy

Trotta Francesco – Head of the HTA Division at the Italian Medicines Agency (AIFA), Italy